1290117-21-3

Basic information

• Product Name: 3-Bromo-4-fluoro-5-nitrobenzoic acid
• Synonyms: 3-Bromo-4-fluoro-5-nitrobenzoic acid
• CAS NO: 1290117-21-3
• Molecular Formula: C₇H₃BrFNO₄
• Molecular Weight: 264.0054232
• Mol File: 1290117-21-3.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 387.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.967±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.15±0.10(Predicted)
• CAS DataBase Reference: 3-Bromo-4-fluoro-5-nitrobenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-4-fluoro-5-nitrobenzoic acid(1290117-21-3)
• EPA Substance Registry System: 3-Bromo-4-fluoro-5-nitrobenzoic acid(1290117-21-3)

Safety Data

• Hazardous Substances Data: 1290117-21-3(Hazardous Substances Data)

Usage

Uses

3-Bromo-4-fluoro-5-nitrobenzoic Acid is a derivative of m-Nitrobenzoic Acid (N494700), a reagent used in the coupling of allyl acetate to allylic, aliphatic and benzylic alcohols.

Upstream product

• 453-71-4 3-nitro-4-fluorobenzoic acid 
• 456-22-4 4-Fluorobenzoic acid 

Downstream Products

• 1353101-96-8 3-bromo-4-fluoro-5-nitro-benzoic acid ethyl ester 
• 1386459-79-5 3-amino-5-bromo-4-fluoro-benzoic acid ethyl ester 

Relevant articles and documents

N-CYCLOHEXYL-5-(THIAZOL-5-YL)-1H-INDOLE-7-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS CD38 INHIBITORS FOR INCREASING NAD+ AND FOR THE TREATMENT OF E.G. MUSCULAR DISORDERS

The present invention is directed to a compound of Formula (I) or a pharmaceutically acceptable salt thereof. Compounds of Formula (I) are CD38 inhibitors, which can be used to treat a disease or condition in a subject that benefits from an increase in NAD+ or to treat a mitochondrial disorder in a subject. Such disease or condition is a muscle structure disorder, a neuronal activation disorder, a muscle fatigue disorder, a muscle mass disorder, a metabolic disease, a cancer, a vascular disease, an ocular vascular disease, a muscular eye disease, or a renal disease. The present description discloses the synthesis and characterisation of exemplary compounds as well as pharmacological data thereof (e.g. pages 30 to 135; examples 1 to 61; table). Such an exemplary compound is e.g. N-((1r,4r)-4-(2-methoxyethoxy) cyclohexyl)-5-(thiazol-5-yl)-1H-indole-7-carboxamide (II).

Macro-cyclic immuno-modulator

The invention provides a macro-cyclic immuno-modulator, and discloses a compound shown as a formula I, and a tautomer, an enantiomer, a pharmaceutically acceptable salt, a crystal form, hydrate or solvate thereof. Experiment results show that the compound can be effectively combined with STING and has a good STING protein excitation function. Therefore, the compound can be used as an STING agonist, can be used to treat various related diseases, and has a very good application prospect in preparing medicines for treating diseases related to STING activity, especially medicines for treating inflammatory and autoimmune diseases, infectious diseases, cancers or precancerous syndromes.

STK4 INHIBITORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES

The application relates to compounds of Formula (I'): which modulate the activity of a kinase (e.g., STK4), a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease or disorder associated with the modulation of a kinase, such as STK4.